Overview

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

Status:
Recruiting

Trial end date:
2023-09-28

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects and how well light dosimetry system works during photodynamic therapy with porfimer sodium in treating participants with malignant mesothelioma or non-small cell lung cancer with pleural disease undergoing surgery. Light dosimetry measures the amount of laser light given during photodynamic therapy. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to light. The activated drug may kill tumor cells. Using light dosimetry for intraoperative photodynamic therapy may help doctors estimate how much light is delivered during photodynamic therapy and decide if the treatment should be stopped or continued.

Phase:

Phase 1

Details

Lead Sponsor:

Roswell Park Cancer Institute

Collaborator:

National Cancer Institute (NCI)

Treatments:

Dihematoporphyrin Ether
Hematoporphyrin Derivative
Trioxsalen